Flputnam Investment Management Co. grew its stake in Stryker Corporation (NYSE:SYK - Free Report) by 64.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 137,133 shares of the medical technology company's stock after buying an additional 53,552 shares during the quarter. Flputnam Investment Management Co.'s holdings in Stryker were worth $43,175,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. State Street Corp grew its stake in shares of Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company's stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC grew its stake in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company's stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the period. Wellington Management Group LLP increased its holdings in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Stryker during the 4th quarter valued at approximately $1,822,272,000. Hedge funds and other institutional investors own 77.09% of the company's stock.
Stryker Price Performance
Stryker stock opened at $338.80 on Monday. The company's fifty day moving average price is $324.61 and its 200 day moving average price is $333.40. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The stock has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker's payout ratio is currently 36.48%.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on SYK shares. Citizens Jmp decreased their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research note on Monday, August 3rd. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Canaccord Genuity Group cut their price objective on shares of Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. Finally, Royal Bank Of Canada lowered their target price on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $386.28.
Get Our Latest Research Report on SYK
Insider Activity
In related news, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
